A new AI-driven blood test could soon keep thousands of women out of the imaging room by ruling out womb cancer with near-perfect accuracy.

For decades, the path to ruling out womb cancer has relied on invasive, uncomfortable transvaginal ultrasounds. It is a bottleneck that causes immense patient anxiety and clogs hospital queues. Now, a trial of an AI-driven blood test on over 16,000 patients in Yorkshire suggests we can bypass this step entirely for low-risk patients.

A shift in triage

The blood test uses machine learning to analyze signals in the blood, categorizing patients by risk. In the trial, it ruled out gynecological cancers with 99% accuracy. This is not about replacing doctors. It is about smarter triage.

If deployed widely, the technology could spare up to 18,000 women annually from undergoing unnecessary, invasive scans. That is roughly one in five current referrals.

The bottleneck problem

The real value here is operational sanity. Health systems are buckling under referral backlogs. By filtering out low-risk patients before they ever reach an imaging clinic, hospitals can reallocate scarce scanning resources to those who actually need them.

This shift aligns with a broader push toward liquid biopsies. But implementation is where these tools usually stall. Training staff and updating referral pathways takes time that overstretched clinics do not have.

Clinicians must trust the algorithm’s negative predictive value. If a test misses even a fraction of a percent of aggressive cancers, the legal and clinical fallout is severe. The tech works in a controlled cohort, but the next hurdle is convincing risk-averse health systems to let software make the first cut.